Collaborations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 07, 2020	May 09, 2019	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cost reimbursement payment received					$ 10,000
Unbilled accounts receivable			$ 3,800		3,800
Research and development			48,117	$ 43,877	$ 136,111	$ 121,115
Remaining research term of collaboration					2 years 3 months 18 days
Revenue recognized			4,728	9,551	$ 30,707	30,687
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 150,000
Collaboration agreement transaction price	150,000
Revenue recognized recorded in deferred revenue			4,700	7,100		22,100
Unsatisfied performance obligation			43,800		43,800		$ 54,900
Milestone receivable			0		0
Research and development					0
Revenue recognized					22,300		14,500
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	120,000
Revenue recognized recorded in deferred revenue			4,000	4,500	19,800	14,500
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	30,000
Revenue recognized recorded in deferred revenue			700	2,600	2,500	7,600
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,480,000
Commercial Milestone Payments	700,000
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,000,000
Commercial Milestone Payments	$ 400,000
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue					8,400
Unsatisfied performance obligation			$ 0		0		$ 8,400
Initial research term of collaboration		4 years
Extended research term of collaboration		1 year
Revenue recognized				$ 2,500	$ 8,400	$ 8,600
Vertex Agreement | Series B-1 Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		$ 55,900
Non refundable upfront payment received		$ 50,000
Issuance of shares, Shares		3,059,695
Stock issued price per share		$ 6.54
Preferred stock premium		$ 5,900
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones		$ 170,000